Isotechnika Pharma Inc IPHAF

Is Lux in a bad spot?

[teevee]

If the FDA decision effectively delays approvals, there are a few  questions that come to mind:
1. How long can ISA keep the doors open?
2. If ISA goes under, does  Lux's deal with ISA die?
3. If Lux's deal dies with ISA, does Lux have a side bar deal with Paladin, or is Lux effectively forced to support ISA by advancing some of the milestone payments early in exchange for some sort of renegotiated deal? 
4. Would it make any sense for Lux to do a reverse takeover of ISA?

[Plato5]

Four good questions from teevee. I presume that any response must be purely speculative. it will all depend on the reasons for the delay - if there is a delay. If it is clear from the FDA decision that the drug is certainly a go - pending the resolution of issues which can clearly be addressed, ISA will certainly be able to raise any necessary bridge funding needed to bring to the drug to market -

[teevee]

I doubt bridge financing is available unless from LUX. ISA's last loan was secured by the patents. Paladin owns the patents now. ISA has little if any assets to secure a loan with. The only way I see ISA obtaining bridge financing from LUX is if ISA's solvency threatens LUX's partnership on voclosporin.